Comparison of montelukast and mometasone furoate in the prevention of recurrent nasal polyps.

Erkan Vuralkan, Cem Saka, Istemihan Akin, Sema Hucumenoglu, Binnur Uzmez Unal, Gokhan Kuran, Berrak Ocal

Journal: Therapeutic advances in respiratory disease 2012;6(1):5-10

PMID: 22042749

Abstract

BACKGROUND

The aim of our study was to compare the effects of montelukast and mometasone furoate nasal spray on the postoperative course of patients with nasal polyposis.

PATIENTS AND METHODS

Fifty patients diagnosed with nasal polyposis between March 2006 and August 2007 were included in the study. All patients underwent bilateral endoscopic sphenoethmoidectomy and were randomized postoperatively into two groups. Group A (n = 25) received 10 mg montelukast per day and group B (n = 25) received 400 µg mometasone furoate nasal spray twice daily. All patients were followed up for 6 months. Sino-Nasal Outcome Test (SNOT)-22 scores, polyp grades, computerized tomography (CT) scores (Lund-Mackay), eosinophils in peripheral blood and polyp tissue were evaluated before and after surgery.

RESULTS

There was a significant reduction in SNOT-22 scores in both groups throughout the study period. There was a significant difference in the recurrence rate between both groups with a marginal advantage of mometasone furoate nasal spray. Eosinophils in peripheral blood were found to be effective on the recurrence rate (p < 0.05).

CONCLUSIONS

In conclusion, both drugs seem to have a complementary action and further studies are needed to determine which patients should receive which treatment.

Address: Department of Otorhinolaryngology Clinic, Trabzon Numune Research and Training Hospital, Trabzon, Turkey. erkanvuralkan@ hotmail.com
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.